192 related articles for article (PubMed ID: 28729054)
1. Isosorbide-based peptidomimetics as inhibitors of hepatitis C virus serine protease.
Portela AC; Barros TG; Lima CHDS; Dias LRS; Azevedo PHRA; Dantas ASCL; Mohana-Borges R; Ventura GT; Pinheiro S; Muri EMF
Bioorg Med Chem Lett; 2017 Aug; 27(16):3661-3665. PubMed ID: 28729054
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease.
Alexandre FR; Brandt G; Caillet C; Chaves D; Convard T; Derock M; Gloux D; Griffon Y; Lallos L; Leroy F; Liuzzi M; Loi AG; Moulat L; Musiu C; Parsy C; Rahali H; Roques V; Seifer M; Standring D; Surleraux D
Bioorg Med Chem Lett; 2015 Sep; 25(18):3984-91. PubMed ID: 26231161
[TBL] [Abstract][Full Text] [Related]
3. Potent aza-peptide derived inhibitors of HCV NS3 protease.
Venkatraman S; Wu W; Shih NY; George Njoroge F
Bioorg Med Chem Lett; 2009 Aug; 19(16):4760-3. PubMed ID: 19596195
[TBL] [Abstract][Full Text] [Related]
4. Structural modeling of HCV NS3/4A serine protease drug-resistance mutations using end-point continuum solvation and side-chain flexibility calculations.
Hotiana HA; Haider MK
J Chem Inf Model; 2013 Feb; 53(2):435-51. PubMed ID: 23305404
[TBL] [Abstract][Full Text] [Related]
5. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
Johansson PO; Bäck M; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
Bioorg Med Chem; 2006 Aug; 14(15):5136-51. PubMed ID: 16675222
[TBL] [Abstract][Full Text] [Related]
6. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease.
Ren J; Ojeda I; Patel M; Johnson ME; Lee H
Bioorg Med Chem Lett; 2019 Aug; 29(16):2349-2353. PubMed ID: 31201062
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus NS3/4A protease.
Kwong AD; Kim JL; Rao G; Lipovsek D; Raybuck SA
Antiviral Res; 1999 Feb; 41(1):67-84. PubMed ID: 10321580
[TBL] [Abstract][Full Text] [Related]
8. Analogs design, synthesis and biological evaluation of peptidomimetics with potential anti-HCV activity.
Lasheen DS; Ismail MA; Abou El Ella DA; Ismail NS; Eid S; Vleck S; Glenn JS; Watts AG; Abouzid KA
Bioorg Med Chem; 2013 May; 21(10):2742-55. PubMed ID: 23583031
[TBL] [Abstract][Full Text] [Related]
9. The design and synthesis of potent inhibitors of hepatitis C virus NS3-4A proteinase.
Attwood MR; Bennett JM; Campbell AD; Canning GG; Carr MG; Conway E; Dunsdon RM; Greening JR; Jones PS; Kay PB; Handa BK; Hurst DN; Jennings NS; Jordan S; Keech E; O'Brien MA; Overton HA; King-Underwood J; Raynham TM; Stenson KP; Wilkinson CS; Wilkinson TC; Wilson FX
Antivir Chem Chemother; 1999 Sep; 10(5):259-73. PubMed ID: 10574181
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
Li X; Liu Y; Zhang YK; Plattner JJ; Baker SJ; Bu W; Liu L; Zhou Y; Ding CZ; Zhang S; Kazmierski WM; Hamatake R; Duan M; Wright LL; Smith GK; Jarvest RL; Ji JJ; Cooper JP; Tallant MD; Crosby RM; Creech K; Wang A
Bioorg Med Chem Lett; 2012 Dec; 22(24):7351-6. PubMed ID: 23142614
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches.
Ezat AA; Elshemey WM
Life Sci; 2019 Jan; 217():176-184. PubMed ID: 30528183
[TBL] [Abstract][Full Text] [Related]
12. A novel high throughput screening assay for HCV NS3 serine protease inhibitors.
Berdichevsky Y; Zemel R; Bachmatov L; Abramovich A; Koren R; Sathiyamoorthy P; Golan-Goldhirsh A; Tur-Kaspa R; Benhar I
J Virol Methods; 2003 Feb; 107(2):245-55. PubMed ID: 12505640
[TBL] [Abstract][Full Text] [Related]
13. Toward the Synthesis of Fluorinated Analogues of HCV NS3/4A Serine Protease Inhibitors Using Methyl α-Amino-β-fluoro-β-vinylcyclopropanecarboxylate as Key Intermediate.
Milanole G; Andriessen F; Lemonnier G; Sebban M; Coadou G; Couve-Bonnaire S; Bonfanti JF; Jubault P; Pannecoucke X
Org Lett; 2015 Jun; 17(12):2968-71. PubMed ID: 26053226
[TBL] [Abstract][Full Text] [Related]
14. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus.
Morikawa K; Lange CM; Gouttenoire J; Meylan E; Brass V; Penin F; Moradpour D
J Viral Hepat; 2011 May; 18(5):305-15. PubMed ID: 21470343
[TBL] [Abstract][Full Text] [Related]
15. Identification of potential inhibitors for HCV NS3 genotype 4a by combining protein-ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation.
El-Hasab MAE; El-Bastawissy EE; El-Moselhy TF
J Biomol Struct Dyn; 2018 May; 36(7):1713-1727. PubMed ID: 28531373
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel phosphonate derivatives as hepatitis C virus NS3 protease inhibitors.
Sheng XC; Pyun HJ; Chaudhary K; Wang J; Doerffler E; Fleury M; McMurtrie D; Chen X; Delaney WE; Kim CU
Bioorg Med Chem Lett; 2009 Jul; 19(13):3453-7. PubMed ID: 19477126
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C Virus NS3/4A Inhibition and Host Immunomodulation by Tannins from
Patil VS; Harish DR; Vetrivel U; Roy S; Deshpande SH; Hegde HV
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164341
[No Abstract] [Full Text] [Related]
18. Molecular and Structural Mechanism of Pan-Genotypic HCV NS3/4A Protease Inhibition by Glecaprevir.
Timm J; Kosovrasti K; Henes M; Leidner F; Hou S; Ali A; Kurt Yilmaz N; Schiffer CA
ACS Chem Biol; 2020 Feb; 15(2):342-352. PubMed ID: 31868341
[TBL] [Abstract][Full Text] [Related]
19. QSAR and docking studies of HCV NS3 serine protease inhibitors.
da Cunha EF; Matos KS; Ramalho TC
Med Chem; 2013 Sep; 9(6):774-805. PubMed ID: 23140577
[TBL] [Abstract][Full Text] [Related]
20. High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors.
Lee JC; Yu MC; Lien TW; Chang CF; Hsu JT
Assay Drug Dev Technol; 2005 Aug; 3(4):385-92. PubMed ID: 16180993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
